How a poorly structured service agreement can inadvertently disqualify tens of millions in tax-free gains under IRC §1202
If you're building a healthcare MSO with an eye toward a liquidity event, there's a good chance someone recently told you about Qualified Small Business Stock (QSBS) treatment under Internal Revenue Code §1202. Maybe your tax advisor mentioned it in passing. Maybe a PE group asked about it during diligence. Maybe you read that your competitor structured around it, and you're wondering what you missed.
Here's what you need to know: §1202 can eliminate federal tax on up to $10 million (now $15 million for stock issued on or after July 5, 2025) of gain per shareholder when you sell your MSO. For a founder with $20 million in gains, that's roughly $5 million kept rather than paid to the IRS. Not a rounding error.
But here's the part nobody tells you until it's too late: the way you've structured your management fees to your friendly PC, specifically, how those fees were set historically based on growth assumptions that may not have materialized, can silently disqualify your entire exit from QSBS treatment. Not because you did anything intentionally wrong. But because the industry evolved, priorities shifted, and what made perfect sense in 2019 became a technical "violation" of the tax code by 2025.
This article walks through exactly how that happens, why it's showing up more in healthcare deals now, and how to think about restructuring your MSO-to-PC fee arrangement to preserve QSBS eligibility.
The 2025 Changes That Made This Relevant
Let's start with why accountants are suddenly talking about this.
Congress expanded §1202 in July 2025 as part of the "One Big Beautiful Bill Act." The changes apply to stock issued on or after July 5, 2025:
- Gross assets ceiling: Raised from $50M to $75M (measured at issuance)
- Per-issuer exclusion cap: Raised from $10M to $15M per taxpayer
- Accelerated holding periods: New partial exclusions at 3 years (50%), 4 years (75%), and 5 years (100%), compared to the old all or nothing 5-year requirement
For stock issued before July 5, 2025, the old rules still apply: $50M gross assets cap, $10M exclusion limit, strict 5-year holding period.
Why this matters for MSOs: Many healthcare services companies that were bumping up against the old $50M threshold now have room to grow while preserving QSBS. And the faster vesting schedule makes exit planning on a 3-to-4-year horizon more viable. The result? QSBS planning moved from "nice to have" to "table stakes" for any MSO considering a sale.
QSBS Basics: The Tests Your MSO Must Pass
IRC §1202 has both shareholder-level and corporation-level requirements. Let's focus on the corporate tests, because that's where MSO structures get complicated.
The Core Corporate Requirements (IRC §1202(c) and (e))
Your MSO must satisfy these tests during "substantially all" of the shareholder's holding period:
C-Corporation Status (§1202(c)(1))
Only C-corps qualify. Your S-corp or LLC won't work unless you convert, and even then you need fresh issuance post-conversion.Gross Assets ≤ Threshold at Issuance (§1202(d))
$50M for stock issued before July 5, 2025; $75M for stock issued on or after July 5, 2025. Measured as aggregate gross assets (cash + FMV of property).Active Business Use: 80% Requirement (§1202(e)(1))
At least 80% of the corporation's assets (by value) must be used in the "active conduct" of one or more qualified trades or businesses.
This is where the trouble starts. Buried in the active business test is §1202(e)(5), which provides that stock or securities in other corporations (except subsidiaries where you own more than 50%) count against your 80% active business requirement.
Translation: If more than 10% of your MSO's assets (by value, net of liabilities) consists of stock or securities in other corporations that aren't your subsidiaries, you fail the active business test.
"Securities" is broadly defined under IRC §1202(e)(4) to include any stock, bond, debenture, or other evidence of indebtedness. That includes formal promissory notes, loan agreements, convertible debt, and any corporate obligation beyond ordinary trade payables.
The distinction matters: Formal notes or other corporate debt instruments from a non-subsidiary PC are generally treated as "securities" that count toward the 10% cap, whereas ordinary trade receivables arising from the provision of services are typically treated as operating assets, not portfolio securities. This is why the moment you formalize an unpaid balance as a note, you've crossed into dangerous territory for QSBS purposes.
Why Healthcare MSOs Walk Into This Trap
Here's the thing: if you structured your MSO between 2017 and 2022, you made decisions that were completely rational given the landscape at the time. The problem is that the landscape shifted underneath you, and nobody warned you that yesterday's best practice might become tomorrow's QSBS disqualifier.
The Evolution of the Problem
Phase 1: The CPOM Issue (2015–2018)
In the early days of digital health, the defining challenge was the corporate practice of medicine doctrine. Tech founders couldn't legally provide clinical services. The friendly PC structure solved that: a physician-owned professional corporation handles clinical care while the MSO (owned by founders and investors) handles everything else.
Phase 2: The Capital Trap (2018–2021)
Once the friendly PC structure became standard, a new fear emerged: capital getting permanently trapped at the PC level.
Investors put money into the MSO. The MSO built the infrastructure, hired the team, bought the software, and paid for marketing. Revenue came in at the PC. But investors at the MSO level were worried they'd never see returns because cash would sit in an entity they didn't own.
The Solution: Aggressive Fee Structures Based on Growth Projections
The rational response was to maximize the value flowing from the PC to the MSO through management fees. But here's where things get tricky.
To remain compliant with arm's length standards, most groups engaged valuation experts to perform fair market value (FMV) analyses. These FMV studies often identified and carved out intellectual property owned by the MSO (i.e., proprietary software, clinical protocols, brand value, patient acquisition methods, etc.). The analyses would conclude that, given the value of this IP and the services the MSO provides, a substantial management fee was justified.
Armed with these FMV studies, groups would then set fixed management fees in advance based on projected growth. The fee might be structured to cover 100 full-time employees supporting the clinical operations, or assume the MSO would be managing $15 million in annual revenue by year-end, or reflect anticipated infrastructure buildout.
Everyone was trying to do the right thing. Set the fees in advance. Document the rationale. Get the FMV study. Be compliant.
But then reality happened. The business grew slower than projected. Market conditions changed. Hiring took longer than expected. That fixed management fee that assumed 100 FTEs? The MSO only ended the year with 50. The fee that assumed $15 million in revenue? Collections came in at $9 million.
The management fee was overstated. Not because anyone was trying to be aggressive. Not because anyone was gaming the system. But because people were trying to be compliant by setting things in advance based on reasonable projections that simply didn't materialize.
Phase 3: When Filing Consolidated Returns Made It Invisible (For Some)
Here's why this didn't always feel like a problem: Some groups were able to file consolidated tax returns, treating the MSO and PC as a single taxpayer for federal income tax purposes.
Federal consolidated returns under IRC §1504 require 80% ownership (by vote and value) of common stock. In most friendly PC structures, the MSO doesn't legally own 80% of the PC because of state corporate practice of medicine restrictions. However, some groups obtained IRS private letter rulings recognizing "beneficial ownership" sufficient for consolidation based on the economic benefits and burdens of ownership, but that's fact-specific.
For the groups that could consolidate, unpaid management fees sitting on the books as intercompany receivables were less problematic from a tax perspective. Intercompany balances washed out on the combined return.
Phase 4: The QSBS Pivot (2023–2025)
Then two things happened almost simultaneously.
First, QSBS became significantly more valuable. The 2025 statutory expansion, combined with a softening M&A market that made founders more sensitive to after-tax proceeds, put §1202 front and center in exit planning.
Second, sophisticated tax advisors started digging into the §1202 look-through rules and realized something. If the MSO owns more than 50% of the PC (by vote or value), then under IRC §1202(e)(5)(A) and (C), you look through to the PC's assets and activities for QSBS purposes. This happens automatically based on ownership, regardless of whether you're filing consolidated returns or not.
That look-through has two effects:
First, intercompany stock and debt get disregarded, which would solve the note receivable problem. That sounds good.
But second, you also look through to what the PC actually does. And if the PC is practicing medicine, you've potentially imported excluded "health" services under §1202(e)(3)(A) into your MSO's qualified trade or business analysis. That's bad.
While there's promising recent guidance suggesting that nonclinical, administrative MSOs might not be considered "health" services for §1202 purposes, most advisors started landing on the safer position: Preserve the MSO as a pure administrative and operational entity.
The new conventional wisdom became: Avoid crossing the 50% ownership threshold to protect QSBS qualification.
The Unintended Consequence
Here's where everything unravels: If the PC isn't a more than 50% subsidiary under §1202(e)(5)(C), either because you don't legally own more than 50% or you're intentionally avoiding that ownership to sidestep both CPOM restrictions and the QSBS health services taint, those intercompany balances become a problem.
That $1.2 million note receivable from the PC to the MSO? If you were among the groups that could file consolidated returns, it washed out on a combined balance sheet from an income tax perspective. But for QSBS purposes, if the PC isn't a subsidiary, that note is a security of another corporation under IRC §1202(e)(4).
And if your MSO has $8 million in net assets, and $1.2 million of that is a note from the PC, you're at 15% securities. You've blown the 10% limit. You've failed the active business test under §1202(e)(1)(A).
The management fee structure that made perfect sense when you built it, based on credible FMV analyses, designed to solve the capital trap problem, and workable for those who could consolidate for income tax purposes, has now become a QSBS disqualifier because the business didn't grow as fast as projected.
Why This Feels Particularly Unfair
You set those fees in good faith. The growth projections were reasonable at the time. The FMV studies were defensible. You were trying to do everything by the book.
And you're right to feel that way. But the IRS doesn't care about intent or reasonableness when it comes to the mathematical tests under §1202. The 10% securities limit is mechanical. If the note is there, and it's over 10% of net asset value during the holding period, you've got a problem.
The IRS and courts haven't established a bright-line test for what "substantially all" means, but many practitioners interpret it as requiring compliance for approximately 80% to 90% or more of the holding period. So if you breach the 10% limit for even a meaningful portion of a shareholder's holding period, you risk tainting the stock.
The good news: If you're reading this now, you still have time to address it.
The Management Fee Calculation Fix
The solution isn't to eliminate management fees or to pretend the MSO doesn't deserve substantial compensation for the value it creates. The MSO absolutely should be paid for its services, its IP, its infrastructure, and its operational support.
The solution is to rethink how those fees are structured so that unpaid amounts don't accumulate into formalized notes in the first place.
Understanding Your Fee Structure Options
There are three primary ways MSOs charge PCs for services, and each has different implications for the note accumulation problem:
- Fixed Fee Structures
A fixed monthly or quarterly amount: "PC pays MSO $150,000 per month."
The appeal: Predictable cash flow for the MSO. Simple to administer. Easy to defend if properly benchmarked to FMV studies.
The QSBS risk: If the PC has a weak collections month or quarter, the fee is still contractually due. Where does that obligation go? Straight onto the balance sheet as a note receivable. This is exactly how most groups ended up with the note accumulation problem in the first place.
- Cost Plus Arrangements
The MSO calculates its actual costs allocable to the PC, adds a markup, and bills that amount: "PC pays MSO's direct costs plus X% margin."
The appeal: It tracks economic reality because the MSO gets reimbursed for what it actually spends. It naturally flexes with business activity.
The QSBS risk: Better than fixed fees because the amount due is tied to actual expenditures rather than projections. But you still face timing mismatches. If the MSO spends $200K in January but the PC only collects $180K that month, you've got a $20K deficit that needs to be addressed.
- Percentage of Revenue
The fee is calculated as a percentage of PC collections: "PC pays MSO 25% of net revenue."
The appeal: Perfectly aligned with PC cash flow. Automatically scales up and down with business performance. Intuitive and easy to explain.
The significant compliance issue: In many states, percentage-based management fees can implicate fee-splitting prohibitions or anti-kickback concerns under state medical practice acts. Some state medical boards view percentage of revenue arrangements as improper referral compensation or as the unlicensed practice of medicine.
This creates a real problem for groups operating multi-state platforms. Many MSOs foreign qualify PCs into a single state (Florida and Texas are popular choices) for operational simplicity. But if you're doing that, you need to ensure your management fee structure complies with the strictest state medical board in your entire footprint.
As a result, many sophisticated MSO operators avoid pure percentage of revenue structures altogether, even if they might be permissible in some jurisdictions, because the compliance risk and administrative burden of tracking state-by-state rules simply isn't worth it.
The QSBS consideration: If percentage of revenue structures are permissible under applicable state law, they can actually be one of the safer approaches from a QSBS perspective. The fee is inherently tied to actual collections, which means the PC theoretically never owes more than it has collected.
The Bottom Line
If you're an MSO founder or operator who structured aggressive management fees between 2018 and 2022, you weren't wrong. You were solving the problem in front of you with the information and incentives available at the time. Investors needed returns. Everyone was terrified of capital getting trapped. Fair market value studies supported substantial fees. For the few groups that could file consolidated returns, the intercompany mechanics were manageable. The structure worked for its intended purpose.
But the world changed. QSBS went from obscure tax provision to core value driver seemingly overnight. The very mechanism that solved your capital distribution problem—management fees based on growth projections that created intercompany notes when those projections didn't fully materialize, became the technical violation that threatens to cost you millions in unnecessary tax at exit.
The answer isn't to abandon management fees. The MSO deserves fair compensation for the genuine value it provides. The answer is to restructure prospectively so that fees reflect current business reality rather than outdated projections, and to ensure unpaid fees don't accumulate into large formalized notes that breach the 10% securities limit.
You've spent years building something of genuine value. You've navigated CPOM restrictions, recruited physicians, built infrastructure, and created a business that actually works. Now it's time to make sure your management fee structure doesn't cost you millions at exit because of a technical provision nobody warned you about until it was too late.